Fiche publication
Date publication
mars 2018
Journal
Journal of the National Comprehensive Cancer Network : JNCCN
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Mascaux C, Tsao MS, Hirsch FR
Lien Pubmed
Résumé
Precision medicine commonly refers to the selection of the most effective cancer treatments based on the presence of specific biomarkers (eg, genomic abnormalities) in a patient's tumor. Therefore, genomic testing is used to identify patients whose tumors harbor the vulnerability that is sensitive to corresponding targeted therapies. This approach allows for the selection of patients who have the greatest chance of deriving benefit from the treatments, reduces toxicity, and significantly improves outcome; precision medicine is recommended for advanced non-small cell lung cancer. This article reviews the evolution of genomic testing in lung cancer, from its development, including first success and failures, to its current use in the care of patients with lung cancer, and addresses future considerations, such as the expected increase of targetable abnormalities, the need to follow the genomic profile over time, and tumor heterogeneity.
Mots clés
Biomarkers, Tumor, Genetic Testing, methods, Genomics, methods, Humans, Lung Neoplasms, diagnosis, Molecular Targeted Therapy, Mutation, Neoplasm Staging, Prognosis
Référence
J Natl Compr Canc Netw. 2018 03;16(3):323-334
